Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00314873
Status:
COMPLETED
Last Update Posted:
2014-06-03
First Post:
2006-04-13
Brief Title:
Pilot Study of Imatinib Gleevec as Treatment for Advanced Thymic Carcinoma
Sponsor:
Indiana University School of Medicine
Organization:
Indiana University
Study Overview
Official Title:
Pilot Study of Imatinib Gleevec as Treatment for Advanced Thymic Carcinoma
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is important to demonstrate if single agent activity is noted for patients with thymic tumors over expressing c-kit andor PDGF If this current trial is positive it opens the door to evaluate other combination of drugs with imatinib in thymic tumors
Detailed Description:
Thymic carcinomas are particularly more concerning due to their aggressive metastatic nature and shorter overall survival in comparison to their lesser-malignant thymoma counterparts This necessitates the need for systemic therapy Due to the paucity of thymic carcinoma cases the ideal regimen for locally advanced or metastatic thymic carcinomas is not definedTo this point there has not been a study using imatinib in thymic tumors expressing the KIT tyrosine kinase protein or PDGF tyrosine kinase protein This study is important to demonstrate if single agent activity is noted for patients with thymic tumors over expressing c-kit andor PDGF If this current trial is positive it opens the door to evaluate other combination of drugs with imatinib in thymic tumors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None